All news 21.03.2019



Prof. Vardareli is a well-known specialist in the sphere of Nuclear Medicine with more than 20-year experience

On 22 March (Friday) at 2 pm in the conference hall at Acibadem City Clinic Tokuda Hospital on 9th floor, prof. Erkan Vardareli, the Chief of the Nuclear Medicine Department at Acibadem Altunzade Hospital, Turkey, is delivering a presentation under the title: "Innovative PET-CT Examination with Specific Biomarker 68Ga-PSMA at Diagnosis of Prostate Carcinoma and Therapy with 177Lu PSMA”.

The presentation gave the opportunity for a highly reliable examination for prostate carcinoma cancers that starting to be performed Nuclear Medicine Department at Acibadem City Clinic Oncology Center at the end of March.

The event will be moderated by Prof. Irena Kostadinova, the Chief of the Nuclear Medicine Department at Acibadem City Clinic – Oncology Center.




New hybrid imaging method for prostate carcinoma patients 

This innovative examination optimizes the treatment plan, saves costly procedures and a lot of troubles for the patient.

Since the end of March 2019 the Nuclear Medicine Department at Acibadem City Clinic – Oncology Center have started hybrid diagnosis of prostate carcinoma /PC/ with new radiopharmaceutical in accordance with the latest world trends.  The new examination helps the physicians to visualize the relapse /tumour tissues that have newly appeared after the radical treatment/ in prostate carcinoma patients.

The end effect of the innovative diagnostics is a change pf the therapy of up to 54% of the patients and order of personalized treatment. 10% of the patient with early stages - their treatment plan develops into a radical one and the patient is expected to recover fully. The optimization of the treatment plan saves resources of other expensive invasive and non-invasive examinations and therapies.

Currently, magnetic-resonance imaging and contrast computer tomography is used for PC staging to visualize the relapses but they are not always accurate enough at low levels of the tumour marker. The implementation of the new radiopharmaceutical 68Ga-PSMA in combination with molecular imaging and CT gives the opportunity to the physicians to visualize the pathological changes at an earlier stage and with low values of the tumour marker. 


Research is being carried out to use 68Ga-PSMA PET-CT in the relapse of brain tumours and primary hepatocellular carcinoma.  The initial comparative data of this radiopharmaceutical with 68Ga-PSMA PET-CT shows its lower sensitivity when detecting metastasis in lymph nodes of sizes less than 10 mm; its implementation in intraopreative detection with a gamma probe. The results ought to be summarized based on a bigger number of patients.

The Nuclear Medicine Department at Acibadem City Clinic- Oncology Center has the most sensitive PET-CT with 5-ring sensor giving the unique opportunity to examine cancer patients for a shorter period of time and with smaller quantity of applied radioactive substance.